OncoOne, a Klosterneuburg, Austria, developer of multiple drug modalities to target oxidized macrophage migration inhibitory factor (oxMIF), raised €13M in Series A funding.

Investors included the Austrian Research Promotion Agency (FFG), the Austria Wirtschaftsservice Gesellschaft (AWS), and two family offices.

The initial funding will enable the company to develop its solutions to provide innovative treatments for cancer indications with poor prognosis.

Founded by Randolf Kerschbaumer, PhD, Michael Thiele, PhD and Alexander Schinagl, PhD, OncoOne will develop several drug modalities to target oxidized macrophage migration inhibitory factor (oxMIF), an isoform of macrophage migration inhibitory factor (MIF) and a new drug target in solid tumor cancer indications.

FinSMEs19/03/2020 | To read full story, visit https://startuparound.com/read/1584613907.7205925/OncoOne-Raises-€13M-in-Series-A-Funding?ref=audio_experience